Navigation Links
EMIT Corporation Receives FDA 510(k) Clearance for HypothermX™ Blood and Fluid Warmer.

HOUSTON, May 26 2011 /PRNewswire/ -- EMIT Corporation announced today that it has received U.S. Food and Drug Administration 510(k) clearance to market the HypothermX™ HX100 device.  The HypothermX™ HX100 device is a patent protected portable fluid warming device designed to warm intravenous fluids, blood or blood products infused into a patient to prevent or treat trauma, environmental, procedure related, or induced hypothermia.  Heating is accomplished via a flameless hydrocarbon combustion process.  

"HypothermX HX100 is the first truly light weight (< 3.0 lbs), portable, long-term (>4 hours continuous use) solution to offer actual therapeutic warming in the field for injured patients.  HypothermX HX100 is capable of  warming up to 5 liters of saline introduced at 15 degrees C and 15 units of packed red blood cells  introduced at 5 degrees C to 38 degrees C +/- 3 degrees C with an infusion rate between 50 ml/min and 200 ml/min and ambient conditions between 0 degrees C and 40 degrees C.  The system has numerous safety features and provides the user with the ability to temporarily silence alarms based on operational needs," stated Mr. Sheldon, EMIT Corporation Founder, Chairman & CEO.   

"Our market clearance represents a significant milestone for the company and we will begin an aggressive sales and marketing campaign in the military and civilian market sectors this quarter," said Mr. Sheldon Mr. Sheldon went on to say that "hypothermia continues to plague the military and civilian first responder markets and our device will result in life saving interventions at the point of injury."

About EMIT Corporation

EMIT Corporation is focused on the design, development, manufacture, and sale of devices and related products for the treatment and prevention of hypothermia.  The HypothermX™ HX100 and ancillary products were invented by Charles Cox, Jr., MD and Brijesh Gill, MD and exclusively licensed from The University of Texas Health Science Center at Houston and The University of Texas at Austin following nearly $4.0 million of research and development funding provided by the United States Army Telemedicine and Advanced Technology Research Center.  EMIT Corporation raised an additional $2.4 million from CitareTx Investment Partners, a Texas based medical device investment fund and business incubator, also founded and managed by Mr. Sheldon.  

Contact: Jeffery J. Sheldon - Founder, Chairman & CEO, EMIT Corporation, +1-281-984-7355, , or fax, +1-281-984-7374, or mobile, +1-832-455-3173,

SOURCE EMIT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement From Volcano Corporation on Latest St. Jude Lawsuit
2. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
3. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
4. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
5. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
6. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
7. SenSage Named Cerner Corporations Accelerate Partner of the Year
8. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
9. Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of Americas Largest Corporations
10. Omeros Corporation Reports First Quarter 2011 Financial Results
11. Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
Post Your Comments:
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):